DermTech
Updated: January 20, 2026
John Dobak, President and CEO
Country: USA | Funding: $259.9M (+)
Website: https://dermtech.com/
DermTech is a global leader in molecular dermatology, implementing precision medicine methods in the diagnosis and treatment of skin diseases. The company developed DermTech test for the early detection of melanoma and personalized selection of drug therapy. This noninvasive genomic test uses DermTech Smart Stickers to evaluate questionable melanocytic lesions that meet one or more ABCDE criteria. It identifies genomic markers associated with melanoma to differentiate benign lesions from those at higher risk. The test has a negative predictive value of 99%, meaning that a negative test result indicates a 99% probability that the lesion is not melanoma.
Website: https://dermtech.com/
DermTech is a global leader in molecular dermatology, implementing precision medicine methods in the diagnosis and treatment of skin diseases. The company developed DermTech test for the early detection of melanoma and personalized selection of drug therapy. This noninvasive genomic test uses DermTech Smart Stickers to evaluate questionable melanocytic lesions that meet one or more ABCDE criteria. It identifies genomic markers associated with melanoma to differentiate benign lesions from those at higher risk. The test has a negative predictive value of 99%, meaning that a negative test result indicates a 99% probability that the lesion is not melanoma.
